CLDX

Neutral

[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity

Celldex Therapeutics, Inc. (CLDX) reported insider trading activity where director Denice Torres was granted 26,000 non-qualified stock options. These...

Stock Titan 4 days ago 0

Bullish

Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight

The Chronic Spontaneous Urticaria (CSU) market is experiencing significant growth, driven by increased disease awareness, improved diagnosis, and a ri...

Yahoo! Finance Canada 1 week ago 0

Bullish

Barzolvolimab leaves 64% of CSU patients angioedema-free 7 months after dosing

Celldex (NASDAQ: CLDX) reported positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU) patients with angioedema, ...

Stock Titan 2 weeks ago 0

Bullish

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex announced long-term results from its Phase 2 study of barzolvolimab, revealing rapid, significant, and durable improvements in angioedema for ...

Yahoo Finance Singapore 2 weeks ago 0